Searched for: person:rosena23
in-biosketch:true
Editor's Notebook: August 2024 [Editorial]
Rosenkrantz, Andrew B
PMID: 39197108
ISSN: 1546-3141
CID: 5687432
Radiologist Workforce Attrition from 2019 to 2024: A National Medicare Analysis
Rosenkrantz, Andrew B; Cummings, Ryan W
PMID: 39041939
ISSN: 1527-1315
CID: 5701842
The Neiman Imaging Comorbidity Index: Development and Validation in a National Commercial Claims Database
Pelzl, Casey E; Rosenkrantz, Andrew B; Rula, Elizabeth Y; Christensen, Eric W
OBJECTIVE:To build the Neiman Imaging Comorbidity Index (NICI), based on variables available in claims datasets, which provides good discrimination of an individual's chance of receiving advanced imaging (CT, MR, PET), and thus, utility as a control variable in research. METHODS:This retrospective study used national commercial claims data from Optum's deidentified Clinformatics Data Mart database from the period January 1, 2018 to December 31, 2019. Individuals with continuous enrollment during this 2-year study period were included. Lasso (least absolute shrinkage and selection operator) regression was used to predict the chance of receiving advanced imaging in 2019 based on the presence of comorbidities in 2018. A numerical index was created in a development cohort (70% of the total dataset) using weights assigned to each comorbidity, based on regression β coefficients. Internal validation of assigned scores was performed in the remaining 30% of claims, with comparison to the commonly used Charlson Comorbidity Index. RESULTS:The final sample (development and validation cohorts) included 10,532,734 beneficiaries, of whom 2,116,348 (20.1%) received advanced imaging. After model development, the NICI included nine comorbidities. In the internal validation set, the NICI achieved good discrimination of receipt of advanced imaging with a C statistic of 0.709 (95% confidence interval [CI] 0.708-0.709), which predicted advanced imaging better than the CCI (C 0.692, 95% CI 0.691-0.692). Controlling for age and sex yielded better discrimination (C 0.748, 95% CI 0.748-0.749). DISCUSSION/CONCLUSIONS:The NICI is an easily calculated measure of comorbidity burden that can be used to adjust for patients' chances of receiving advanced imaging. Future work should explore external validation of the NICI.
PMID: 38276924
ISSN: 1558-349x
CID: 5625402
Editor's Notebook: May 2024
Rosenkrantz, Andrew B
PMID: 38810113
ISSN: 1546-3141
CID: 5663612
The Yellow Journal Goes Multimedia [Editorial]
Rosenkrantz, Andrew B
PMID: 38598355
ISSN: 1546-3141
CID: 5664712
Editor's Notebook: March 2024
Rosenkrantz, Andrew B
PMID: 38536405
ISSN: 1546-3141
CID: 5644912
Editor's Notebook: January 2024
Rosenkrantz, Andrew B
PMID: 38294321
ISSN: 1546-3141
CID: 5627102
The Yellow Journal: A Look Back at 2023 [Editorial]
Rosenkrantz, Andrew B
PMID: 38090809
ISSN: 1546-3141
CID: 5589272
An Examination of Racial and Ethnic Disparities in the Use of Prostate Biopsy and Magnetic Resonance Imaging in Prostate Cancer Screening
Chartrand, Nicholas; Stecher, Chad; Rajendra, Shubhsri; Rosenkrantz, Andrew B.; Duszak, Richard; Hughes, Danny R.
Introduction:We assessed racial and ethnic disparities in the use of prostate biopsy or MRI following an elevated PSA result.Methods:We retrospectively evaluated insurance claims from Optum's de-identified Clinformatics Data Mart database from January 1, 2011 to December 31, 2017. This was a large commercially insured cohort from across the United States. We included all male enrollees over 40 years old receiving an elevated PSA result with no prior prostate biopsy or MRI and no confirmed urinary tract infection within 6 weeks of PSA test.Results:A total of 765,409 participants met inclusion criteria with 43,711 (5.71%) receiving a PSA result above 4 ng/mL. Of these, 7,399 received either a prostate biopsy or MRI within 180 days. Men between ages 40-54 (29.48%) were most likely to receive prostate biopsy or MRI after an elevated PSA, followed by those between 55-64 (24.91%), 65-74 (18.56%), 75-84 (6.33%), and above 85 (3.62%). Compared to White patients, Black patients were more likely to receive either a prostate biopsy or MRI (OR: 1.16, 95% CI: 1.01, 1.32) following an elevated PSA level, while Asian (OR: 0.72, 95% CI: 0.54, 0.96) and Hispanic (OR: 0.83, 95% CI: 0.70, 0/97) patients were less likely.Conclusions:Physicians appear to be following the reported statistical incidence of prostate cancer by race and ethnicity when using prostate biopsy or MRI for patients with elevated PSA levels. These results demonstrate the importance of publishing statistical data on disease incidence by race and ethnicity for informing physicians' decision-making.
SCOPUS:85180267925
ISSN: 2352-0779
CID: 5621232
Reply by Authors
Chartrand, Nicholas; Stecher, Chad; Rajendra, Shubhsri; Rosenkrantz, Andrew B.; Duszak, Richard; Hughes, Danny R.
SCOPUS:85180324600
ISSN: 2352-0779
CID: 5621212